A detailed history of Creative Planning transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Creative Planning holds 490,783 shares of BMY stock, worth $28.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
490,783
Previous 531,970 7.74%
Holding current value
$28.3 Million
Previous $22.1 Million 14.96%
% of portfolio
0.03%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$39.66 - $51.75 $1.63 Million - $2.13 Million
-41,187 Reduced 7.74%
490,783 $25.4 Million
Q2 2024

Aug 15, 2024

BUY
$40.25 - $52.99 $6 Million - $7.9 Million
149,088 Added 38.94%
531,970 $22.1 Million
Q1 2024

May 10, 2024

BUY
$47.98 - $54.4 $1.97 Million - $2.23 Million
40,960 Added 11.98%
382,882 $20.8 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $1.02 Million - $1.22 Million
-21,110 Reduced 5.81%
341,922 $17.5 Million
Q3 2023

Nov 16, 2023

BUY
$57.89 - $64.73 $1.06 Million - $1.18 Million
18,243 Added 5.29%
363,032 $21.1 Million
Q2 2023

Jul 21, 2023

BUY
$63.71 - $70.74 $1.16 Million - $1.29 Million
18,214 Added 5.58%
344,789 $22 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $251,406 - $285,151
-3,826 Reduced 1.16%
326,575 $22.6 Million
Q4 2022

Feb 10, 2023

BUY
$68.48 - $81.09 $1.21 Million - $1.44 Million
17,705 Added 5.66%
330,401 $23.8 Million
Q3 2022

Nov 03, 2022

BUY
$0.13 - $76.84 $401 - $237,435
3,090 Added 1.0%
312,696 $22.2 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $2.94 Million - $3.24 Million
40,506 Added 15.05%
309,606 $23.8 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $408,657 - $490,016
6,647 Added 2.53%
269,100 $19.7 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $443,841 - $517,415
-8,276 Reduced 3.06%
262,453 $16.4 Million
Q3 2021

Nov 10, 2021

SELL
$59.17 - $69.31 $242,478 - $284,032
-4,098 Reduced 1.49%
270,729 $16 Million
Q2 2021

Aug 04, 2021

SELL
$61.91 - $67.42 $3.87 Million - $4.21 Million
-62,457 Reduced 18.52%
274,827 $18.4 Million
Q1 2021

Apr 30, 2021

SELL
$59.34 - $66.74 $137,134 - $154,236
-2,311 Reduced 0.68%
337,284 $21.3 Million
Q4 2020

Jan 29, 2021

BUY
$57.74 - $65.43 $878,802 - $995,844
15,220 Added 4.69%
339,595 $21.1 Million
Q3 2020

Nov 05, 2020

BUY
$57.43 - $63.64 $1.11 Million - $1.23 Million
19,276 Added 6.32%
324,375 $19.6 Million
Q2 2020

Jul 23, 2020

BUY
$54.82 - $64.09 $22,531 - $26,340
411 Added 0.13%
305,099 $17.9 Million
Q1 2020

May 05, 2020

SELL
$46.4 - $67.43 $914,358 - $1.33 Million
-19,706 Reduced 6.07%
304,688 $17 Million
Q4 2019

Jan 30, 2020

BUY
$49.21 - $64.19 $2.02 Million - $2.64 Million
41,139 Added 14.52%
324,394 $20.8 Million
Q3 2019

Nov 01, 2019

BUY
$42.77 - $50.71 $14,156 - $16,785
331 Added 0.12%
283,255 $14.4 Million
Q2 2019

Jul 26, 2019

SELL
$44.62 - $49.34 $188,162 - $208,066
-4,217 Reduced 1.47%
282,924 $12.8 Million
Q1 2019

Apr 24, 2019

SELL
$45.12 - $53.8 $375,353 - $447,562
-8,319 Reduced 2.82%
287,141 $13.7 Million
Q4 2018

Feb 01, 2019

SELL
$48.76 - $63.23 $12,921 - $16,755
-265 Reduced 0.09%
295,460 $15.4 Million
Q3 2018

Oct 25, 2018

BUY
$55.19 - $62.25 $902,963 - $1.02 Million
16,361 Added 5.86%
295,725 $18.4 Million
Q2 2018

Jul 20, 2018

SELL
$50.53 - $62.98 $511,666 - $637,735
-10,126 Reduced 3.5%
279,364 $15.5 Million
Q1 2018

Apr 18, 2018

SELL
$59.92 - $68.98 $787,049 - $906,052
-13,135 Reduced 4.34%
289,490 $18.3 Million
Q4 2017

Jan 17, 2018

BUY
$59.94 - $65.35 $1.93 Million - $2.1 Million
32,141 Added 11.88%
302,625 $18.5 Million
Q3 2017

Oct 17, 2017

BUY
$55.23 - $63.74 $14.9 Million - $17.2 Million
270,484
270,484 $17.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.